Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 3, 2007, Pages 223-229

  Roohbakhsh, Ali ^a   Moghaddam, Akbar Hajizadeh ^b   Massoudi, Roohollah ^c   Zarrindast, Mohammad Reza ^c  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MAZANDARAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety; Cannabinoids; Interaction; Nitric oxide; Plus maze test; Rat

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANXIOLYTIC AGENT; ARGININE; CANNABINOID RECEPTOR; KETAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; MALE; MAZE TEST; NONHUMAN; PROTEIN INTERACTION; RAT; STEREOTAXIC SURGERY; WISTAR RAT;

ANALGESICS; ANIMALS; ANXIETY; ARGININE; CANNABINOIDS; ENZYME INHIBITORS; HIPPOCAMPUS; MALE; MICROINJECTIONS; MORPHOLINES; NAPHTHALENES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; STEREOTAXIC TECHNIQUES;

EID: 33846429160     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04576.x     Document Type: Article

References (45)

1. Chaperon F, Thiebot MH. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 1999; 13: 243-81.
2. Rodgers RJ, Haller J, Halasz J, Mikics E. One-trial sensitization to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 2003; 17: 1279-86.
3. Hollister LE. Health aspects of cannabis. Pharmacol. Rev. 1986; 38: 1-20.
4. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76: 245-50.
5. Williamson EM, Evans FG. Cannabinoids in clinical practice. Drugs 2000; 60: 1303-14.
6. 9- tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 2002; 135: 564-78.
7. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276: 2050-4.
8. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviors and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 2001; 70: 123-31.
9. Sulcova A, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 1998; 59: 347-52.
10. 9-tetrahydrocannabinol. Psychopharmacology 2002; 163: 111-17.
11. McGregor IS, Dastur FN, McLellan RA, Brown RE. Cannabinoid modulation of rat pup ultrasonic vocalizations. Eur. J. Pharmacol. 1996; 313: 43-9.
12. Navarro M, Hernandez E, Munoz RM et al. Acute administration of CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491-6.
13. Akinshola BE, Chakrabarti A, Onaivi ES. In vitro and in vivo action of cannabinoids. Neurochem. Res. 1999; 24: 1233-40.
14. Haller J, Bakos N, Szimay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 2002; 16: 1395-8.
15. Degroot A, Nomikos GG. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur. J. Neurosci. 2004; 20: 1059-64.
16. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005; 81: 331-42.
17. Rawls SM, Tallarida RJ, Gray AM, Gellen EB, Adler MW. L-NAME, a nitric oxide synthase inhibitor, and WIN55212-2, a cannabinoid agonist, interact to evoke synergistic hypothermia. J. Pharmacol. Exp. Ther. 2004; 308: 780-6.
18. Spina E, Trovati A, Parolaro D, Giagnoni G. A role of nitric oxide in WIN 55,212-2 tolerance. Eur. J. Pharmacol. 1998; 343: 157-63.
19. Bredt DS, Snyder SH. Isolation of nitric oxide syntethase, a calmodulin-requiring enzyme. Proc. Natl Acad. Sci. USA 1990; 87: 682-5.
20. Triet D, Degroot A. Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shoke-probe tests. Brain Res. 2002; 949: 60-70.
21. File SE, Kenny PJ, Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav. 2000; 66: 65-72.
22. Pellow S, Chopin P, File SE, Brily M. Validation of open: Closed arms entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985; 14: 149-67.
23. Rodgers RJ, Johnson NJT. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995; 52: 297-303.
24. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press, San Diego. 1998.
25. Rezayat M, Roohbakhsh A, Zarrindast MR, Massoudi R, Djahanguiri B. Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol. Behav. 2005; 84: 775-82.
26. Katona I, Sperlagh B, Sik A et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999; 19: 4544-58.
27. Chakrabarti A, Ekuta JE, Onaivi ES. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Res. Bull. 1998; 45: 67-74.
28. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP55,940 in the social interaction test. Pharmacol. Biochem. Behav. 2004; 77: 567-73.
29. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611-16.
30. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus-maze. J. Pharmacol. Exp. Ther. 1998; 285: 813-19.
31. Genn RF, Tucci S, Marco E, Viveros MP, File SE. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP55,940 in animal tests of anxiety. J. Psychopharmacol. 2003; 17: A27.
32. 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency cure-shift electrical brain stimulation paradigm in three different rat strains. Life. Sci. 1996; 58: L365-72.
33. McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP55,940 in rats. Pharmacol. Biochem. Behav. 1996; 53: 657-64.
34. Arnold JC, Topple AN, Maller PE, Hunt GE, McGregor IS. The distribution of cannabinoid-induced Fos expression in rat brain: Differences between the Lewis and Wistar strain. Brain Res. 2001; 921: 240-55.
35. Wenger T, Jamali KA, Juaneda C, Leonardelli J, Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 1997; 237: 724-8.
36. 37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 1996; 276: 56-64.
37. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1 specific agents. Behav. Pharmacol. 2004; 15: 299-304.
38. Kathmann M, Weber B, Schlicker E. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn Schmiedebergs Arch. Pharmacol. 2001; 363: 50-6.
39. Gessa GL, Casu MA, Carta G, Mascia MS. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR141716A. Eur. J. Pharmacol. 1998; 355: 119-24.
40. Kurt M, Bilge SS, Aksoz E, Kukula O, Celik S, Kesim Y. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol. J. Pharmacol. 2004; 56: 353-7.
41. Volke V, Soosaar A, Koks S, Vasar E, Mannisto PT. L-Arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. Eur. J. Pharmacol. 1998; 351: 287-90.
42. Monzon ME, Varas MM, De Barioglio SR. Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melatonin-concentrating hormone (MCH) in rat brain. Peptides 2001; 22: 1043-7.
43. Getting SJ, Segieth J, Ahmad S, Biggs CS, Whitton PS. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Res. 1996; 717: 196-9.
44. Lonart G, Wang J, Johnson KM. Nitric oxide induces neurotransmitter release from hippocampal slices. Eur. J. Pharmacol. 1992; 220: 271-2.
45. Huang AM, Lee EH. Role of hippocampal nitric oxide in memory retention in rats. Pharmacol. Biochem. Behav. 1995; 50: 327-32.